C4 Therapeutics
CCCC
101 hedge funds and large institutions have $153M invested in C4 Therapeutics in 2025 Q4 according to their latest regulatory filings, with 24 funds opening new positions, 44 increasing their positions, 19 reducing their positions, and 16 closing their positions.
386% more call options, than puts
Call options by funds: $738K | Put options by funds: $152K
132% more repeat investments, than reductions
Existing positions increased: 44 | Existing positions reduced: 19
50% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 16
31% more capital invested
Capital invested by funds: $117M → $153M (+$35.9M)
8.57% more ownership
Funds ownership: 73.82% → 82.39% (+8.6%)
4% more funds holding
Funds holding: 97 → 101 (+4)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
Top Sellers
| 1 |
O
OrbiMed
New York
|
-$9.07M |
| 2 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
-$7.7M |
| 3 |
TCM
Tang Capital Management
San Diego,
California
|
-$2M |
| 4 |
Millennium Management
New York
|
-$1.77M |
| 5 |
WA
Wasatch Advisors
Salt Lake City,
Utah
|
-$1.2M |
CCCC Hedge Fund Activity: Q4 2025 in Review
101 of the 8,223 institutional investors tracked by Wall St. Rank reported a position in C4 Therapeutics (CCCC) for Q4 2025, worth a combined $153M — up 31% from $117M a quarter earlier.
Buyers outnumbered sellers: 24 funds opened new CCCC positions and 16 closed out — a net gain of 8 holders — while 44 added to existing stakes and 19 trimmed.
The largest buyer was Point72 Asset Management, opening a new position worth an estimated $22.4M. The largest seller was OrbiMed, cutting an estimated $9.07M.
- 101 institutional investors held C4 Therapeutics (CCCC) as of Q4 2025, up from 97 in Q3 2025.
- Funds reported $153M of C4 Therapeutics stock for Q4 2025, up 31% quarter-over-quarter.
- 24 funds opened new C4 Therapeutics positions in Q4 2025 and 16 closed out, a net change of +8 holders.
- The largest C4 Therapeutics buyer in Q4 2025 was Point72 Asset Management, an estimated $22.4M added.
- The largest C4 Therapeutics seller in Q4 2025 was OrbiMed, an estimated $9.07M sold.
Based on aggregated 13F filings for Q4 2025.